Études translationnelles de mTOR dans l'inflammation et le cancer

 

Arnold Kristof

Université McGill

 

Domaine : santé circulatoire et respiratoire

Programme chercheurs-boursiers cliniciens - Senior

Concours 2015-2016

I study how a protein called ‘mammalian target of rapamycin', or mTOR, controls the survival or death of cells.  mTOR senses the levels of amino acids, which are building blocks for the synthesis of new proteins.  When amino acids are low, mTOR tells the cell to shut down energy consuming process, and to stop growing.  Prolonged amino acid ‘starvation' can lead to cell death.  On the other hand, too much mTOR activity leads to inappropriate cell growth and survival, which is a feature of cancer. 

In this proposal, we will study the complex cellular mechanisms by which dietary reduction in amino acids increases cell death and lung damage during bacterial infection.  We also study a disease called lymphangioleiomyomatosis, or LAM, which is a cancer-like condition of the lung caused by excessive mTOR activity.  We found a novel drug target which will be tested in mice as a potential therapy for LAM.  Our studies on mTOR will reveal new therapeutic approaches that can be used in human subjects to prevent or treat diseases of the lung.